[go: up one dir, main page]

NO995900L - Retroviral vector particles formed in a baculovirus expression system - Google Patents

Retroviral vector particles formed in a baculovirus expression system

Info

Publication number
NO995900L
NO995900L NO995900A NO995900A NO995900L NO 995900 L NO995900 L NO 995900L NO 995900 A NO995900 A NO 995900A NO 995900 A NO995900 A NO 995900A NO 995900 L NO995900 L NO 995900L
Authority
NO
Norway
Prior art keywords
expression system
retroviral vector
particles formed
baculovirus expression
vector particles
Prior art date
Application number
NO995900A
Other languages
Norwegian (no)
Other versions
NO995900D0 (en
Inventor
Alan John Kingsman
Ian Martin Jones
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Publication of NO995900D0 publication Critical patent/NO995900D0/en
Publication of NO995900L publication Critical patent/NO995900L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

En sammensetning er beskrevet. Sammensetningen omfatter minst en baculoviral komponent og minst en retroviral komponent, hvor den retrovirale komponent kan pakkes inn i en retroviral partikkel.A composition is described. The composition comprises at least one baculoviral component and at least one retroviral component, wherein the retroviral component can be packed into a retroviral particle.

NO995900A 1997-06-04 1999-12-02 Retroviral vector particles formed in a baculovirus expression system NO995900L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711578.6A GB9711578D0 (en) 1997-06-04 1997-06-04 Novel retroviral vector production systems
PCT/GB1998/001626 WO1998055640A1 (en) 1997-06-04 1998-06-04 Retroviral vector particles produced in a baculovirus expression system

Publications (2)

Publication Number Publication Date
NO995900D0 NO995900D0 (en) 1999-12-02
NO995900L true NO995900L (en) 2000-02-04

Family

ID=10813571

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995900A NO995900L (en) 1997-06-04 1999-12-02 Retroviral vector particles formed in a baculovirus expression system

Country Status (11)

Country Link
EP (1) EP0986649A1 (en)
JP (1) JP2002510204A (en)
KR (1) KR20010013332A (en)
CN (1) CN1259171A (en)
AU (1) AU741764B2 (en)
CA (1) CA2289491A1 (en)
GB (1) GB9711578D0 (en)
IL (1) IL132359A0 (en)
NO (1) NO995900L (en)
NZ (1) NZ500936A (en)
WO (1) WO1998055640A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
ATE386821T1 (en) 2000-10-23 2008-03-15 Gen Probe Inc COMPOSITIONS AND METHODS FOR DETECTING HUMAN IMMUNODEFICIENCY VIRUS 2 (HIV-2)
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
TWI477602B (en) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2241626B1 (en) 2008-01-09 2016-01-06 Konkuk University Industrial Cooperation Corp Baculovirus-based vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001029A1 (en) * 1987-07-24 1989-02-09 Cetus Corporation Airlift insect cell culture
AU651311B2 (en) * 1988-03-21 1994-07-21 Chiron Corporation Recombinant retroviruses
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
GB9510272D0 (en) * 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors

Also Published As

Publication number Publication date
WO1998055640A1 (en) 1998-12-10
AU741764B2 (en) 2001-12-06
GB9711578D0 (en) 1997-07-30
NZ500936A (en) 2001-11-30
CN1259171A (en) 2000-07-05
AU7780098A (en) 1998-12-21
EP0986649A1 (en) 2000-03-22
KR20010013332A (en) 2001-02-26
NO995900D0 (en) 1999-12-02
IL132359A0 (en) 2001-03-19
JP2002510204A (en) 2002-04-02
CA2289491A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
ATE224183T1 (en) CONDITIONING SHAMPOO COMPOSITION
DE69515891D1 (en) COMPOSITE AND SUCTIONABLE LAUNDRY PIECE WITH THIS COMPOSITE
DE69607952D1 (en) ORGANOBORAN-POLYAMINE COMPLEXES AND ADHESIVE COMPOSITIONS PRODUCED WITH THEM
AU134374S (en) Container for wipes or the like
DE69801976D1 (en) Composition and article with improved compression set
DE69106714D1 (en) Hypoglykämische hydroxyharnstoffderivate.
DE69130300D1 (en) Photocrosslinkable and light-insoluble coating composition with halomethyl-1,3,5-triazine functions
ITMI940575A0 (en) DAMPER OPERATING SELECTIVELY IN THE FREQUENCY
GB2285806B (en) Alkali-treated bagasse,and its preparation and uses
ID29052A (en) 3,3-BIARILPIPERIDINE AND 2,2-BIARILMORPHOLINA DECREASES
AP9801289A0 (en) Proc ss fo prep ring ,4-di ydroxypy-ridine and 2,4-dihydroxy-3-nitropyridine
DE69006878D1 (en) Particulate detergent additive, its manufacture and use in detergent compositions.
NO995900L (en) Retroviral vector particles formed in a baculovirus expression system
DK1101053T3 (en) Double ring seal in one piece
AU8876591A (en) Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
PT929299E (en) 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINS AND 2-AMINOCYCLOHEPTA ¬B | BENZOFURANOS SUBSTITUIDOS
DE69528571D1 (en) FILLING HOLES AND THE LIKE IN SUBSTRATES
ZA969402B (en) Novel oligopeptides, the preparation and use thereof.
EP0827082A4 (en) Semiconductor memory having arithmetic function, and processor using the same
ZA9610929B (en) Polymeric particulate materials and compositions containing them.
ES1026518Y (en) BUCKET WITH DRAINER AND PERFECTED MOCHO.
Kang et al. Combined effects of hypoxia and hydrogen sulfide on early developmental stages of white shrimp Metapenaeus monoceros
HRP990290B1 (en) Polymer composition, the production and further processing thereof into receptacles
IL116164A0 (en) Proteins having fibrinolytic and thrombin-inhibiting properties
ES2195405T3 (en) DERIVED FROM TIADIAZOL CARBOXAMIDA, PHYTOSANITARY AGENT, AND USE.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application